66 related articles for article (PubMed ID: 27435393)
1. Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.
Wang WJ; Li CF; Chu YY; Wang YH; Hour TC; Yen CJ; Chang WC; Wang JM
Clin Cancer Res; 2017 Jan; 23(2):503-513. PubMed ID: 27435393
[TBL] [Abstract][Full Text] [Related]
2. Biological significance of MYC and CEBPD coamplification in urothelial carcinoma: Multilayered genomic, transcriptional and posttranscriptional positive feedback loops enhance oncogenic glycolysis.
Chan TC; Chen YT; Tan KT; Wu CL; Wu WJ; Li WM; Wang JM; Shiue YL; Li CF
Clin Transl Med; 2021 Dec; 11(12):e674. PubMed ID: 34954904
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer.
Lu CS; Shieh GS; Wang CT; Su BH; Su YC; Chen YC; Su WC; Wu P; Yang WH; Shiau AL; Wu CL
Oncotarget; 2017 May; 8(19):30844-30858. PubMed ID: 27244887
[TBL] [Abstract][Full Text] [Related]
4. Trimodal therapy effect on survival in urothelial vs non-urothelial bladder cancer.
de Angelis M; Baudo A; Siech C; Jannello LMI; Di Bello F; Goyal JA; Tian Z; Longo N; de Cobelli O; Chun FKH; Saad F; Shariat SF; Carmignani L; Gandaglia G; Moschini M; Montorsi F; Briganti A; Karakiewicz PI
BJU Int; 2024 Mar; ():. PubMed ID: 38494989
[TBL] [Abstract][Full Text] [Related]
5. Association of ABCC2 and CDDP-Resistance in Two Sublines Resistant to CDDP Derived from a Human Nasopharyngeal Carcinoma Cell Line.
Xie SM; Fang WY; Liu TF; Yao KT; Zhong XY
J Oncol; 2010; 2010():915046. PubMed ID: 20628484
[TBL] [Abstract][Full Text] [Related]
6. Metformin promotes apoptosis in hepatocellular carcinoma through the CEBPD-induced autophagy pathway.
Tsai HH; Lai HY; Chen YC; Li CF; Huang HS; Liu HS; Tsai YS; Wang JM
Oncotarget; 2017 Feb; 8(8):13832-13845. PubMed ID: 28099155
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor suppresses prostate cancer metastasis but promotes bladder cancer metastasis via differentially altering miRNA525-5p/SLPI-mediated vasculogenic mimicry formation.
Yang Z; Chen J; Xie H; Liu T; Chen Y; Ma Z; Pei X; Yang W; Li L
Cancer Lett; 2020 Mar; 473():118-129. PubMed ID: 31843555
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib-induced miRNAs direct epigenetic silencing of locus genes and trigger apoptosis in leukemia.
Chu YY; Ko CY; Wang SM; Lin PI; Wang HY; Lin WC; Wu DY; Wang LH; Wang JM
Cell Death Dis; 2017 Nov; 8(11):e3167. PubMed ID: 29120412
[TBL] [Abstract][Full Text] [Related]
9. CCAAT/enhancer-binding protein delta promotes intracellular lipid accumulation in M1 macrophages of vascular lesions.
Lai HY; Hsu LW; Tsai HH; Lo YC; Yang SH; Liu PY; Wang JM
Cardiovasc Res; 2017 Sep; 113(11):1376-1388. PubMed ID: 28859294
[TBL] [Abstract][Full Text] [Related]
10. CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer.
Zhao Y; Yu Y; Li X; Guo A
J Exp Clin Cancer Res; 2024 Apr; 43(1):115. PubMed ID: 38627816
[TBL] [Abstract][Full Text] [Related]
11. Editorial: Prognostic research and precision oncology in upper tract urothelial carcinoma-volume II.
Yang TM; Singla N; Chen CH; Hsieh JT; Yeh HC
Front Oncol; 2023; 13():1276718. PubMed ID: 37736544
[No Abstract] [Full Text] [Related]
12. CEBPD is a master transcriptional factor for hypoxia regulated proteins in glioblastoma and augments hypoxia induced invasion through extracellular matrix-integrin mediated EGFR/PI3K pathway.
Mao XG; Xue XY; Lv R; Ji A; Shi TY; Chen XY; Jiang XF; Zhang X
Cell Death Dis; 2023 Apr; 14(4):269. PubMed ID: 37059730
[TBL] [Abstract][Full Text] [Related]
13. Targeting Transcription Factors ATF5, CEBPB and CEBPD with Cell-Penetrating Peptides to Treat Brain and Other Cancers.
Greene LA; Zhou Q; Siegelin MD; Angelastro JM
Cells; 2023 Feb; 12(4):. PubMed ID: 36831248
[TBL] [Abstract][Full Text] [Related]
14. Syngeneic model of carcinogen-induced tumor mimics basal/squamous, stromal-rich, and neuroendocrine molecular and immunological features of muscle-invasive bladder cancer.
Shah SD; Gillard BM; Wrobel MM; Karasik E; Moser MT; Mastri M; Long MD; Sule N; Brackett CM; Huss WJ; Foster BA
Front Oncol; 2023; 13():1120329. PubMed ID: 36816919
[TBL] [Abstract][Full Text] [Related]
15. The biological impacts of CEBPD on urothelial carcinoma development and progression.
Chan TC; Shiue YL; Li CF
Front Oncol; 2023; 13():1123776. PubMed ID: 36776299
[TBL] [Abstract][Full Text] [Related]
16. TFAP2C Knockdown Sensitizes Bladder Cancer Cells to Cisplatin Treatment via Regulation of EGFR and NF-κB.
Xing J; Chen W; Chen K; Zhu S; Lin F; Qi Y; Zhang Y; Han S; Rao T; Ruan Y; Zhao S; Yu W; Cheng F
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230734
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma.
Hu B; Zou T; Qin W; Shen X; Su Y; Li J; Chen Y; Zhang Z; Sun H; Zheng Y; Wang CQ; Wang Z; Li TE; Wang S; Zhu L; Wang X; Fu Y; Ren X; Dong Q; Qin LX
Cancer Res; 2022 Oct; 82(20):3845-3857. PubMed ID: 36066408
[TBL] [Abstract][Full Text] [Related]
18. CCAAT/Enhancer-Binding Protein Delta Regulates Glioblastoma Survival through Catalase-Mediated Hydrogen Peroxide Clearance.
Lin HY; Lim SW; Hsu TI; Yang WB; Huang CC; Tsai YT; Chang WC; Ko CY
Oxid Med Cell Longev; 2022; 2022():4081380. PubMed ID: 36035213
[TBL] [Abstract][Full Text] [Related]
19. Emerging strategies for the improvement of chemotherapy in bladder cancer: Current knowledge and future perspectives.
Liu S; Chen X; Lin T
J Adv Res; 2022 Jul; 39():187-202. PubMed ID: 35777908
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
